

8/3,AB/3 (Item 3 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 1998 Dialog Corporation. All rts. reserv.

08877886 97078805

Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate.

Firestone CY; Whitehead SS; Collins PL; Murphy BR; Crowe JE Jr

Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-0720, USA.

Virology (UNITED STATES) Nov 15 1996, 225 (2) p419-22, ISSN 0042-6822
Journal Code: XEA

Languages: ENGLISH

Document type: JOURNAL ARTICLE

The complete nucleotide sequence of the **RSV** cpts-248/404 live attenuated vaccine candidate was determined from cloned cDNA and was compared to that of the **RSV** A2/HEK7 wild-type, cold-passaged cp-**RSV**, and cpts-248 virus, which constitute the series of progenitor viruses. **RSV** cpts-248/404 is more attenuated and more **temperature sensitive** (ts) (shut-off temperature 36 degrees) than its cpts-248 parent virus (shut-off temperature 38 degrees) and is currently being evaluated in phase I clinical trials in humans. Our ultimate goal is to identify the genetic basis for the host range attenuation phenotype exhibited by cp-**RSV** (i.e., efficient replication in tissue culture but decreased replication in chimpanzees and humans) and for the ts and attenuation phenotypes of its chemically mutagenized derivatives, cpts-248 and cpts-248/404. Compared with its cpts-248 parent, the cpts-248/404 virus possesses an amino acid change in the polymerase (L) protein and a single nucleotide **substitution** in the M2 gene start sequence. In total, the cpts-248/404 mutant differs from its wild-type **RSV** A2/HEK7 progenitor in seven amino acids [four in the polymerase (L) protein, two in the fusion (F) glycoprotein, and one in the (N) nucleoprotein] and one nucleotide difference in the M2 gene start sequence. Heterogeneity at nucleotide position 4 (G or C, negative sense, compared to G in the **RSV** A2/HEK7 progenitor) in the leader region of vRNA developed during passage of the cpts-248/404 in tissue culture. Biologically cloned derivatives of **RSV** cpts-248/404 virus that differed at position 4 possessed the same level of temperature sensitivity and exhibited the same level of replication in the upper and lower respiratory tract of mice, suggesting that heterogeneity at this position is not clinically relevant. The determination of the nucleotide sequence of the cpts-248/404 virus will allow evaluation of the stability of the eight mutations that are associated with the attenuation phenotype during vaccine production and following replication in humans.

?ds

The invention relates to reshaped human monoclonal antibodies directed against isotypic determinants of immunoglobulin E (IgE), direct equivalents and derivatives of said antibodies. The molecules of the invention are useful for diagnostics, prophylaxis and treatment of allergy.

ABSTRACT WORD COUNT: 39

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF2	938
SPEC A	(English)	EPABF2	16739
Total word count - document A			17677
Total word count - document B			0
Total word count - documents A + B			17677

23/3,AB/4 (Item 2 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 1998 EUROPEAN PATENT OFFICE. All rts. reserv.

00566187

ORDER fax of complete patent from KR SourceOne. See HELP ORDER348

Mutant respiratory syncytial virus (RSV) vaccines containing same and methods of use.

Mutantes respiratorisches Synzytialvirus (RSV), dieses enthaltende Impfstoffe und Verfahren zur Verwendung.

Virus syncytial respiratoire (RSV) mutant, vaccins le contenant et methodes d'utilisation.

PATENT ASSIGNEE:

AMERICAN CYANAMID COMPANY, (212591), 1937 West Main Street P.O. Box 60,
Stamford Connecticut 06904-0060, (US), (applicant designated states:
AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;NL;PT;SE)

INVENTOR:

Randolph, Valerie Bruce, 535 Pine Brook Road, Lincoln Park, New Jersey
07035, (US)

Crowley, Joan Coflan, 261 Glenwood Road, Englewood, New Jersey 07631,
(US)

LEGAL REPRESENTATIVE:

Wachtershauser, Gunter, Dr. (12711), Tal 29, D-80331 Munchen, (DE)

PATENT (CC, No, Kind, Date): EP 567100 A1 931027 (Basic)

APPLICATION (CC, No, Date): EP 93106496 930421;

PRIORITY (CC, No, Date): US 871420 920421

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; NL;
PT; SE

INTERNATIONAL PATENT CLASS: C12N-015/45; C12N-007/08; C12N-015/87;

A61K-048/00; C12N-015/86; A61K-039/155; C07K-013/00;

ABSTRACT EP 567100 A1

This invention provides cold adapted mutant **RSV** , specifically, mutant **RSV** of subgroup A and B. Nucleic acid molecules encoding the mutant **RSV** of this invention, and immunogenic polypeptides of these mutant **RSV** also are provided by this invention. Pharmaceutical compositions containing any of the above compositions are provided herein. These are especially useful as vaccines. Further provided by this invention are methods of vaccinating a subject against **RSV** infection using the pharmaceutical compositions described herein.

ABSTRACT WORD COUNT: 77

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	162
SPEC A	(English)	EPABF1	17098
Total word			

26/3/1 (Item 1 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 1998 Dialog Corporation. All rts. reserv.

09078550 97185152

Identification of mutations contributing to the reduced virulence of a modified strain of respiratory syncytial virus.

Tolley KP; Marriott AC; Simpson A; Plows DJ; Matthews DA; Longhurst SJ; Evans JE; Johnson JL; Cane PA; Randolph VB; Easton AJ; Pringle CR

Biological Sciences Department, University of Warwick, Coventry, UK.

Vaccine (ENGLAND) Dec 1996, 14 (17-18) p1637-46, ISSN 0264-410X

Journal Code: X60

Languages: ENGLISH

Document type: JOURNAL ARTICLE

26/3/12 (Item 12 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 1998 Dialog Corporation. All rts. reserv.

03910901 83144136

Identification of the virus-specific proteins of respiratory syncytial virus temperature-sensitive mutants by immunoprecipitation.

Walsh EE; Hruska JF

Proc Soc Exp Biol Med (UNITED STATES) Feb 1983, 172 (2) p202-6, ISSN 0037-9727 Journal Code: PXZ

Languages: ENGLISH

Document type: JOURNAL ARTICLE

26/3/13 (Item 13 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 1998 Dialog Corporation. All rts. reserv.

03471243 82032294

Antigen and polypeptide synthesis by temperature-sensitive mutants of respiratory syncytial virus.

Pringle CR; Shiroadaria PV; Gimenez HB; Levine S

J Gen Virol (ENGLAND) May 1981, 54 (Pt 1) p173-83, ISSN 0022-1317

Journal Code: I9B

Languages: ENGLISH

Document type: JOURNAL ARTICLE

26/3/15 (Item 1 from file: 348)

DIALOG(R) File 348:EUROPEAN PATENTS

(c) 1998 EUROPEAN PATENT OFFICE. All rts. reserv.

00606382

ORDER fax of complete patent from KR SourceOne. See HELP ORDER348

Reshaped monoclonal antibodies against an immunoglobulin isotype.

Umgestaltete monoklonale Antikörper gegen ein Immunglobulinisotyp.

Anticorps monoclonaux transformés contre une isotype d'immunoglobuline.

PATENT ASSIGNEE:

CIBA-GEIGY AG, (201300), Klybeckstrasse 141, CH-4002 Basel, (CH),

(applicant designated states:

AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;NL;PT;SE)

TANOX BIOSYSTEMS, INC., (1023240), 10301 Stella Link Rd., Houston, TX

77025, (US), (applicant designated states:

AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;NL;PT;SE)

INVENTOR:

Hardman, Norman, Gstaltenrainweg 67, CH-4125 Riehen, (CH)

Kolbinger, Frank, Malteserordensstrasse 1D, D-79114 Freiburg, (DE)

Saldanha, Jose, 22a Lincoln Way, Enfield, Middlesex EN1 1TE, (GB)

LEGAL REPRESENTATIVE:

Schluep, Hans-Peter et al (45372), c/o CIBA GEIGY AG Patentabteilung

Postfach, CH-4002 Basel, (CH)

PATENT (CC, No, Kind, Date): EP 589840 A1 940330 (Basic)
APPLICATION (CC, No, Date): EP 93810653 930915;
PRIORITY (CC, No, Date): GB 9220228 920924; US 952802 920925
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; NL;
PT; SE
INTERNATIONAL PATENT CLASS: C12N-015/13; C12P-021/08; C12N-005/10;
C12N-015/62; A61K-039/395; G01N-033/577; G01N-033/68;
ABSTRACT WORD COUNT: 39

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF2	938
SPEC A	(English)	EPABF2	16739
Total word count - document A			17677
Total word count - document B			0
Total word count - documents A + B			17677

26/3/18 (Item 4 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

(c) 1998 EUROPEAN PATENT OFFICE. All rts. reserv.

00517216

ORDER fax of complete patent from KR SourceOne. See HELP ORDER348

Stable pura vectors and uses thereof.

Stabile pura-Vektoren und ihre Verwendung.

Vecteurs pura stables et leur utilisation.

PATENT ASSIGNEE:

AMERICAN CYANAMID COMPANY, (212591), 1937 West Main Street P.O. Box 60,
Stamford Connecticut 06904-0060, (US), (applicant designated states:
AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;PT;SE)

INVENTOR:

Brey III, Robert Newton, 74 Sagamore Drive, Rochester, New York 14617,
(US)

Fulginiti, James Peter, 5180 Foster Road, Canandaigua, New York 14424,
(US)

Anilionis, Algis, 25 Whistlerhill Lane, Huntington, New York 11743, (US)

LEGAL REPRESENTATIVE:

Wachtershauser, Gunter, Dr. (12711), Tal 29, W-8000 Munchen 2, (DE)

PATENT (CC, No, Kind, Date): EP 512260 A2 921111 (Basic)

EP 512260 A3 930728

APPLICATION (CC, No, Date): EP 92105887 920406;

PRIORITY (CC, No, Date): US 695706 910503

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; PT;
SE

INTERNATIONAL PATENT CLASS: C12N-015/74; A61K-039/112; C12N-015/74;

C12R-001/42

ABSTRACT WORD COUNT: 92

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	514
SPEC A	(English)	EPABF1	8964
Total word count - document A			9478
Total word count - document B			0
Total word count - documents A + B			9478

26/3/25 (Item 11 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

(c) 1998 EUROPEAN PATENT OFFICE. All rts. reserv.

00278345

ORDER fax of complete patent from KR SourceOne. See HELP ORDER348

VACCINES FOR HUMAN RESPIRATORY VIRUS.

IMPfstoffe gegen menschliche respiratorische Viren.

Vaccins contre le virus respiratoire humain.

PATENT ASSIGNEE:

UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, (751080), , Chapel Hill,
North Carolina 27514, (US), (applicant designated states:
AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)

INVENTOR:

WERTZ, Gail, W., 608 Laurel Hill Road, Chapel Hill, NC 27514, (US)

COLLINS, Peter, L., 4703 Saul Road, Kensington, MD 20895, (US)

LEGAL REPRESENTATIVE:

Perry, Robert Edward et al (41331), GILL JENNINGS & EVERY Broadgate House
7 Eldon Street, London EC2M 7LH, (GB)

PATENT (CC, No, Kind, Date): EP 290446 A1 881117 (Basic)

EP 290446 B1 940202

WO 8704185 870716

APPLICATION (CC, No, Date): EP 87900757 861223; WO 86US2756 861223

PRIORITY (CC, No, Date): US 818740 860114

DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS: C12N-015/45; A61K-039/155;

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	191
CLAIMS B	(German)	EPBBF1	194
CLAIMS B	(French)	EPBBF1	227
SPEC B	(English)	EPBBF1	4610
Total word count - document A			0
Total word count - document B			5222
Total word count - documents A + B			5222
?			

27/3/1 (Item 1 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 1998 Dialog Corporation. All rts. reserv.

09096022 97187925

Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene.

Crowe JE Jr; Firestone CY; Whitehead SS; Collins PL; Murphy BR

Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda MD 20892-0720, USA.

Virus Genes (UNITED STATES) 1996, 13 (3) p269-73, ISSN 0920-8569

Journal Code: XEI

Languages: ENGLISH

Document type: JOURNAL ARTICLE

27/3/3 (Item 3 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 1998 Dialog Corporation. All rts. reserv.

08877886 97078805

Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate.

Firestone CY; Whitehead SS; Collins PL; Murphy BR; Crowe JE Jr

Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-0720, USA.

Virology (UNITED STATES) Nov 15 1996, 225 (2) p419-22, ISSN 0042-6822

Journal Code: XEA

Languages: ENGLISH

Document type: JOURNAL ARTICLE

27/3/5 (Item 5 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 1998 Dialog Corporation. All rts. reserv.

08090917 95076702

Attenuated temperature - sensitive respiratory syncytial virus mutants generated by cold adaptation.

Randolph VB; Kandis M; Stemler-Higgins P; Kennelly MS; McMullen YM; Speelman DJ; Weeks-Levy C

Lederle-Praxis Biologicals, Pearl River, NY 10965.

Virus Res (NETHERLANDS) Sep 1994, 33 (3) p241-59, ISSN 0168-1702

Journal Code: X98

Languages: ENGLISH

Document type: JOURNAL ARTICLE

27/3/6 (Item 6 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 1998 Dialog Corporation. All rts. reserv.

08082019 95066335

A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees.

Crowe JE Jr; Bui PT; Davis AR; Chanock RM; Murphy BR

Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.

Vaccine (ENGLAND) Jul 1994, 12 (9) p783-90, ISSN 0264-410X

Journal Code: X60

Languages: ENGLISH

Document type: JOURNAL ARTICLE

27/3/8 (Item 8 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 1998 Dialog Corporation. All rts. reserv.

07524497 93227701
Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers.
Pringle CR; Filipiuk AH; Robinson BS; Watt PJ; Higgins P; Tyrrell DA
Biological Sciences Department, University of Warwick, Coventry, UK.
Vaccine (ENGLAND) 1993, 11 (4) p473-8, ISSN 0264-410X
Journal Code: X60
Languages: ENGLISH
Document type: CLINICAL TRIAL; JOURNAL ARTICLE

27/3/9 (Item 9 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 1998 Dialog Corporation. All rts. reserv.

07418300 92341066
Assignment of mutant tsN19 (complementation group E) of respiratory syncytial virus to the P protein gene.
Caravokyri C; Zajac AJ; Pringle CR
Biological Sciences Department, University of Warwick, Coventry, U.K.
J Gen Virol (ENGLAND) Apr 1992, 73 (Pt 4) p865-73, ISSN 0022-1317
Journal Code: I9B
Languages: ENGLISH
Document type: JOURNAL ARTICLE

27/3/10 (Item 10 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 1998 Dialog Corporation. All rts. reserv.

06839202 92013968
Defective synthesis of envelope proteins by temperature-sensitive mutants representing complementation groups B and D of respiratory syncytial virus.
Caravokyri C; Pringle CR
Department of Biological Sciences, University of Warwick, Coventry, U.K.
J Gen Virol (ENGLAND) Oct 1991, 72 (Pt 10) p2501-8, ISSN 0022-1317
Journal Code: I9B
Languages: ENGLISH
Document type: JOURNAL ARTICLE

27/3/14 (Item 14 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 1998 Dialog Corporation. All rts. reserv.

03910901 83144136
Identification of the virus-specific proteins of respiratory syncytial virus temperature-sensitive mutants by immunoprecipitation.
Walsh EE; Hruska JF
Proc Soc Exp Biol Med (UNITED STATES) Feb 1983, 172 (2) p202-6, ISSN 0037-9727
Journal Code: PXZ
Languages: ENGLISH
Document type: JOURNAL ARTICLE

27/3/15 (Item 15 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 1998 Dialog Corporation. All rts. reserv.

03471243 82032294

Antigen and polypeptide synthesis by temperature- sensitive mutants of respiratory syncytial virus.

Pringle CR; Shiroadaria PV; Gimenez HB; Levine S
J Gen Virol (ENGLAND) May 1981, 54 (Pt 1) p173-83, ISSN 0022-1317
Journal Code: I9B
Languages: ENGLISH
Document type: JOURNAL ARTICLE

27/3/16 (Item 16 from file: 155)

DIALOG(R) File 155:MEDLINE(R)
(c) format only 1998 Dialog Corporation. All rts. reserv.

03200419 77031856

Respiratory syncytial virus ts mutants and nuclear immunofluorescence.

Faulkner GP; Shiroadaria PV; Follett EA; Pringle CR
J Virol (UNITED STATES) Nov 1976, 20 (2) p487-500, ISSN 0022-538X
Journal Code: KCV
Languages: ENGLISH
Document type: JOURNAL ARTICLE

27/3/17 (Item 17 from file: 155)

DIALOG(R) File 155:MEDLINE(R)
(c) format only 1998 Dialog Corporation. All rts. reserv.

03019458 80114502

Respiratory syncytial virus infection in owl monkeys: viral shedding, immunological response, and associated illness caused by wild-type virus and two temperature- sensitive mutants.

Prince GA; Suffin SC; Prevar DA; Camargo E; Sly DL; London WT; Chanock RM
Infect Immun (UNITED STATES) Dec 1979, 26 (3) p1009-13, ISSN 0019-9567
Journal Code: GO7
Languages: ENGLISH
Document type: JOURNAL ARTICLE

27/3/18 (Item 18 from file: 155)

DIALOG(R) File 155:MEDLINE(R)
(c) format only 1998 Dialog Corporation. All rts. reserv.

03004832 79090171

Evaluation of five temperature- sensitive mutants of respiratory syncytial virus in primates: I. Viral shedding, immunologic response, and associated illness.

Richardson LS; Belshe RB; London WT; Sly DL; Prevar DA; Camargo E; Chanock RM
J Med Virol (UNITED STATES) 1978, 3 (2) p91-100, Journal Code: I9N
Languages: ENGLISH
Document type: JOURNAL ARTICLE

27/3/19 (Item 19 from file: 155)

DIALOG(R) File 155:MEDLINE(R)
(c) format only 1998 Dialog Corporation. All rts. reserv.

03004831 79090163

Evaluation of five temperature- sensitive mutants of respiratory syncytial virus in primates: II. Genetic analysis of virus recovered during infection.

Belshe RB; Richardson LS; London WT; Sly DL; Camargo E; Prevar DA; Chanock RM
J Med Virol (UNITED STATES) 1978, 3 (2) p101-10, Journal Code: I9N
Languages: ENGLISH
Document type: JOURNAL ARTICLE

27/3/21 (Item 21 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 1998 Dialog Corporation. All rts. reserv.

02604347 79029786

Seven complementation groups of respiratory syncytial virus temperature-sensitive mutants.

Gimenez HB; Pringle CR

J Virol (UNITED STATES) Sep 1978, 27 (3) p459-64, ISSN 0022-538X

Journal Code: KCV

Languages: ENGLISH

Document type: JOURNAL ARTICLE

27/3/22 (Item 22 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 1998 Dialog Corporation. All rts. reserv.

02463794 78008174

Further characterization of the complementation group B temperature-sensitive mutant of respiratory syncytial virus.

Belshe RB; Richardson LS; Schnitzer TJ; Prevar DA; Camargo E; Chanock RM

J Virol (UNITED STATES) Oct 1977, 24 (1) p8-12, ISSN 0022-538X

Journal Code: KCV

Languages: ENGLISH

Document type: JOURNAL ARTICLE

27/3/25 (Item 25 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 1998 Dialog Corporation. All rts. reserv.

01793114 73245069

Genetic studies of respiratory syncytial virus temperature-sensitive mutants.

Wright PF; Gharpure MA; Hodes DS; Chanock RM

Arch Gesamte Virusforsch (AUSTRIA) 1973, 41 (3) p238-47, ISSN

0003-9012 Journal Code: 73K

Languages: ENGLISH

Document type: JOURNAL ARTICLE

27/3/27 (Item 27 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 1998 Dialog Corporation. All rts. reserv.

01391758 74161920

Genetic alteration in a temperature-sensitive mutant of respiratory syncytial virus after replication in vivo.

Hodes DS; Kim HW; Parrott RH; Camargo E; Chanock RM

Proc Soc Exp Biol Med (UNITED STATES) Apr 1974, 145 (4) p1158-64,

ISSN 0037-9727 Journal Code: PXZ

Languages: ENGLISH

Document type: JOURNAL ARTICLE

27/3/39 (Item 9 from file: 348)

DIALOG(R) File 348:EUROPEAN PATENTS

(c) 1998 EUROPEAN PATENT OFFICE. All rts. reserv.

00334126

ORDER fax of complete patent from KR SourceOne. See HELP ORDER348

CHIMERIC GLYCOPROTEINS CONTAINING IMMUNOGENIC SEGMENTS OF THE GLYCOPROTEINS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS.

CHIMARENGLYKOPROTEINE, ENTHALTEND IMMUNOGENE SEGMENTE DES HUMANEN RESPIRATORISCHEN SYNZYTIALVIRUS.

GLYCOPROTEINES CHIMERIQUES CONTENANT DES SEGMENTS IMMUNOGENIQUES DES
GLYCOPROTEINES DU VIRUS SYNCYTIAL RESPIRATOIRE HUMAIN.

PATENT ASSIGNEE:

THE UPJOHN COMPANY, (230490), 301 Henrietta Street, Kalamazoo, Michigan
49001, (US), (applicant designated states:
AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)

INVENTOR:

WATHEN, Michael, 3183 St. Anthony Drive, Portage, MI 49002, (US)

LEGAL REPRESENTATIVE:

Perry, Robert Edward et al (41331), GILL JENNINGS & EVERY, Broadgate
House, 7 Eldon Street, London EC2M 7LH, (GB)

PATENT (CC, No, Kind, Date): EP 396563 A1 901114 (Basic)
EP 396563 B1 930210
WO 8905823 890629

APPLICATION (CC, No, Date): EP 88909879 881031; WO 88US3784 881031

PRIORITY (CC, No, Date): US 137387 871223

DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS: C07K-013/00; C12N-015/00; A61K-039/155;

C12N-007/00; C12N-001/20; C12N-001/18; C12N-005/00;

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	291
CLAIMS B	(German)	EPBBF1	234
CLAIMS B	(French)	EPBBF1	322
SPEC B	(English)	EPBBF1	11633
Total word count - document A			0
Total word count - document B			12480
Total word count - documents A + B			12480

?ds

28/3/6 (Item 6 from file: 348)
DIALOG(R) File 348:EUROPEAN PATENTS
(c) 1998 EUROPEAN PATENT OFFICE. All rts. reserv.

00451918

ORDER fax of complete patent from KR SourceOne. See HELP ORDER348
RECOMBINANT NEGATIVE STRAND RNA VIRUS EXPRESSION SYSTEMS AND VACCINES.
EXPRESSIONSSYSTEME FUR REKOMBINANTE NEGATIVSTRANG-RNA-VIREN UND IMPFSTOFFE.
VACCINS ET SYSTEMES D'EXPRESSION DE VIRUS ARN RECOMBINANT A BRIN NEGATIF.
PATENT ASSIGNEE:

AVIRON, INC., (1886920), 1450 Rollins Road, Burlingame, CA 94010, (US),
(applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;IT;LI;LU;NL;SE)

INVENTOR:

PALESE, Peter, 414 Highwood Avenue, Leonia, NJ 07605, (US)
PARVIN, Jeffrey, D., 44 Upton Road, Waltham, MA 02154, (US)
KRYSTAL, Mark, 319 Moore Avenue, Leonia, NJ 07605, (US)

LEGAL REPRESENTATIVE:

Horner, Martin Grenville et al (45941), Cruikshank & Fairweather 19 Royal
Exchange Square, Glasgow G1 3AE Scotland, (GB)

PATENT (CC, No, Kind, Date): EP 490972 A1 920624 (Basic)
EP 490972 A1 930331
EP 490972 B1 950809
WO 9103552 910321

APPLICATION (CC, No, Date): EP 90913914 900827; WO 90US4889 900827
PRIORITY (CC, No, Date): US 399728 890828; US 440053 891121; US 527237
900522

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: C12N-015/11; C12N-015/86; C12N-007/01;
C12N-009/12;

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPAB95	1364
CLAIMS B	(German)	EPAB95	1300
CLAIMS B	(French)	EPAB95	1740
SPEC B	(English)	EPAB95	23204
Total word count - document A			0
Total word count - document B			27608
Total word count - documents A + B			27608

?